New Treatment Strategies for Pulmonary Arterial Hypertension
Abstract
No abstract availableKeywords
Funding Information
- Pfizer
- Actelion
- GlaxoSmithKline
- Bayer
This publication has 10 references indexed in Scilit:
- Pulmonary Artery Denervation to Treat Pulmonary Arterial HypertensionJACC, 2013
- Percutaneous pulmonary artery denervation completely abolishes experimental pulmonary arterial hypertension in vivoEuroIntervention, 2013
- Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial HypertensionCirculation, 2013
- Pulmonary Artery Dilatation Correlates With the Risk of Unexpected Death in Chronic Arterial or Thromboembolic Pulmonary HypertensionChest, 2012
- Combination Therapy in Pulmonary Arterial Hypertension: A Meta-AnalysisCardiology, 2011
- Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)European Heart Journal, 2009
- A meta-analysis of randomized controlled trials in pulmonary arterial hypertensionEuropean Heart Journal, 2008
- Transplantation of Autologous Endothelial Progenitor Cells May Be Beneficial in Patients With Idiopathic Pulmonary Arterial Hypertension: A Pilot Randomized Controlled TrialYearbook of Pulmonary Disease, 2008
- Transplantation of Autologous Endothelial Progenitor Cells May Be Beneficial in Patients With Idiopathic Pulmonary Arterial HypertensionJACC, 2007
- Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertensionJournal of Clinical Investigation, 2003